The effects of vitamin A derivative etretinate on the skin of MRL mice.
MRL/Mp-lpr/lpr (MRL/lpr) mice are characterized by the disorder of apoptosis due to defects in Fas antigens and autoimmune symptoms including spontaneous lupus erythematosus (LE)-like skin lesions. MRL/Mp- + / + (MRL/n) mice do not carry the defect of lpr mutation nor do they exhibit skin disorders during the first six months of life. Retinoids are known to inhibit the proliferation of skin fibroblasts, collagen synthesis, modulate immune responses, and apoptosis by Fas ligand upregulation in skin fibroblasts. We examined changes in dermal thickness and appearance of skin disorders in five months old MRL/lpr mice by oral treatment with etretinate, a retinoic acid derivative. Etretinate treated MRL/lpr mice did not have skin lesions or dermatopathological characteristics including an increase in cells infiltrating the dermis. The mean dermal thickness of MRL/lpr and MRL/n mice treated with etretinate decreased significantly and apoptotic cells density in the dermis of MRL/lpr mice with etretinate was significantly higher compared with the control group (P < 0.05) although MRL/lpr mice have a defect within the Fas antigen. We assumed that etretinate reduced dermal thickness, and suppressed the appearance of skin lesions by inducting apoptosis and perhaps regulation of cytokine expression.
Ikeda
T
T
Department of Dermatology, Wakayama Medical University, Wakayama, Japan. t-ikeda@wakayama-med.ac.jp
Nishide
T
T
Ohtani
T
T
Furukawa
F
F
D000284:Administration, Oral; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005050:Etretinate / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D020287:In Situ Nick-End Labeling; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D019463:Mice, Inbred MRL lpr; D012867:Skin / Q000187:drug effects* / Q000473:pathology
D007641:Keratolytic Agents; D005050:Etretinate